{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:14:13Z","timestamp":1793229253691,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008145","name":"Florida Agency for Health Care Administration","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008145","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.schres.2015.05.038","type":"journal-article","created":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T07:31:41Z","timestamp":1435908701000},"page":"194-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: A randomized controlled trial"],"prefix":"10.1016","volume":"166","author":[{"given":"Robert J.","family":"Constantine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Andel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2015.05.038_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders-4th Edition Text Revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.schres.2015.05.038_bb0010","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1192\/bjp.121.5.529","article-title":"A checklist for the diagnosis of schizophrenia","volume":"121","author":"Astrachan","year":"1972","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2015.05.038_bb0015","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2015.05.038_bb0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","article-title":"Antipsychotic polypharmacy in schizophrenia","volume":"25","author":"Barnes","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2015.05.038_bb0025","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2045125314540297","article-title":"The role of long-acting antipsychotics in schizophrenia: a critical appraisal","volume":"4","author":"Brissos","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.schres.2015.05.038_bb0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2015.05.038_bb0035","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10597-009-9288-2","article-title":"Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid","volume":"46","author":"Constantine","year":"2010","journal-title":"Community Ment. Health J."},{"key":"10.1016\/j.schres.2015.05.038_bb0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10597-012-9497-y","article-title":"Improving psychotherapeutic medication prescribing in Florida: implementation of the Florida Medicaid Drug Therapy Management Program (MDTMP)","volume":"49","author":"Constantine","year":"2013","journal-title":"Community Ment. Health J."},{"key":"10.1016\/j.schres.2015.05.038_bb0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2015.05.038_bb0050","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4088\/JCP.11m07074","article-title":"Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial","volume":"73","author":"Covell","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2015.05.038_bb0055","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/ajp.2006.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications","volume":"163","author":"Essock","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2015.05.038_bb0060","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/appi.ajp.2011.10060908","article-title":"Effectiveness of switching from antipsychotic polypharmacy to monotherapy","volume":"168","author":"Essock","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2015.05.038_bb0065","first-page":"1","article-title":"Critical review of antipsychotic polypharmacy in the treatment of schizophrenia","volume":"2","author":"Fleischhacker","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2015.05.038_bb0070","series-title":"Florida Best Practice Psychotherapeutic Medication Guidelines for Adults","author":"Florida Drug Therapy Management Program for Behavioral Health","year":"2011"},{"key":"10.1016\/j.schres.2015.05.038_bb0075","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14740338.2012.683523","article-title":"Safety and tolerability of antipsychotic polypharmacy","volume":"11","author":"Gallego","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.schres.2015.05.038_bb0080","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2015.05.038_bb0085","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1176\/ps.2007.58.7.1007","article-title":"Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego county. 1999-2004","volume":"58","author":"Gilmer","year":"2007","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2015.05.038_bb0090","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/00005053-198911000-00005","article-title":"Multiple versus single antipsychotic drug treatment in chronic psychosis","volume":"177","author":"Godleski","year":"1989","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.schres.2015.05.038_bb0095","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1176\/appi.ps.002022012","article-title":"Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia","volume":"64","author":"Goren","year":"2013","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2015.05.038_bb0100","series-title":"The ECDEU assessment manual for psychopharmacology \u2013 Revised","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2015.05.038_bb0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.schres.2014.07.015","article-title":"Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia","volume":"158","author":"Hatta","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.05.038_bb0110","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jpsychires.2013.08.024","article-title":"Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients","volume":"47","author":"Hori","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2015.05.038_bb0115","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0278-5846(99)00015-9","article-title":"Combined electroconvulsive therapy and clozapine in treatment-refractory schizophrenia","volume":"23","author":"Kales","year":"1999","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.05.038_bb0120","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2013.10.034","article-title":"Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nation-wide study in Hungary","volume":"152","author":"Katona","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.05.038_bb0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2015.05.038_bb0130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/0004867414536931","article-title":"Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life. Findings of the third national survey on use of psychotropic medications in China.","volume":"49","author":"Li","year":"2015","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2015.05.038_bb0135","series-title":"SAS for mixed models","author":"Littell","year":"2006"},{"key":"10.1016\/j.schres.2015.05.038_bb0140","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia","volume":"161","author":"Marder","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2015.05.038_bb0145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","article-title":"National trends in psychotropic medication polypharmacy in office-based psychiatry","volume":"67","author":"Mojtabai","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2015.05.038_bb0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med. Care"},{"key":"10.1016\/j.schres.2015.05.038_bb0155","series-title":"Clinical Guideline","first-page":"82","article-title":"Schizophrenia, 2009. Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update)","author":"National Collaborating Centre for Mental Health","year":"2009"},{"key":"10.1016\/j.schres.2015.05.038_bb0160","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3346\/jkms.2014.29.5.719","article-title":"Patterns of antipsychotic prescription to aptients with schizophrenia in Korea: results from the Health Insurance Review and Assessment Service \u2013 National patient sample","volume":"29","author":"Park","year":"2014","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.schres.2015.05.038_bb0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.schres.2015.05.038_bb0175","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2146\/ajhp130471","article-title":"Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems","volume":"71","author":"Sun","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.schres.2015.05.038_bb0180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1017\/S1461145703004012","article-title":"Revising polypharmacy to a single antipsychotic regimen for patients with schizophrenia","volume":"7","author":"Suzuki","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2015.05.038_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.10075su1.01","article-title":"Antipsychotics in the treatment of schizophrenia","volume":"72","author":"Tandon","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl.1","key":"10.1016\/j.schres.2015.05.038_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0306-4530(02)00109-9","article-title":"The second-generation antipsychotics: similar efficacy but different neuroendocrine side-effects","volume":"28","author":"Tandon","year":"2003","journal-title":"Psychoneuroendoc."},{"key":"10.1016\/j.schres.2015.05.038_bb0195","first-page":"348","article-title":"Strategies for maximizing clinical effectiveness in the treatment of schizophrenia","volume":"12","author":"Tandon","year":"2006","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2015.05.038_bb0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2007.11.033","article-title":"World Psychiatry Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia","volume":"100","author":"Tandon","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.05.038_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2010.05.025","article-title":"Schizophrenia, \u201cJust the facts\u201d 5. Treatment and prevention.","volume":"122","author":"Tandon","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.05.038_bb0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.schres.2012.10.015","article-title":"Interventions to reduce antipsychotic polypharmacy: a systematic review","volume":"143","author":"Tani","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.05.038_bb0215","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.schres.2011.05.013","article-title":"The evolution of antipsychotic switch and polypharmacy in natural practice\u2014a longitudinal perspective","volume":"130","author":"Tsutsumi","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.05.038_bb0220","article-title":"Outcomes of Medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations","volume":"2015","author":"Velligan","year":"2015","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2015.05.038_bb0225","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0269881114562090","article-title":"\u201cFirst do no harm\u201d. A systematic review of the prevalence and management of antipsychotic adverse effects","volume":"29","author":"Young","year":"2015","journal-title":"J. Psychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415003114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415003114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T12:49:24Z","timestamp":1582548564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996415003114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":44,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0920996415003114"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2015.05.038","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2015.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}